vs
Side-by-side financial comparison of Eightco Holdings Inc. (ORBS) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Eightco Holdings Inc. is the larger business by last-quarter revenue ($10.2M vs $9.1M, roughly 1.1× Protalix BioTherapeutics, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -2281.6%, a 2221.3% gap on every dollar of revenue. On growth, Eightco Holdings Inc. posted the faster year-over-year revenue change (-49.9% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-11.0M). Over the past eight quarters, Eightco Holdings Inc.'s revenue compounded faster (13.1% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
ORBS vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $9.1M |
| Net Profit | $-232.5M | $-5.5M |
| Gross Margin | -13.0% | 49.4% |
| Operating Margin | -475.0% | -51.1% |
| Net Margin | -2281.6% | -60.3% |
| Revenue YoY | -49.9% | -49.9% |
| Net Profit YoY | -9183.3% | -184.8% |
| EPS (diluted) | $-2.34 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.2M | $9.1M | ||
| Q3 25 | $5.3M | $17.9M | ||
| Q2 25 | $7.6M | $15.7M | ||
| Q1 25 | $9.9M | $10.1M | ||
| Q4 24 | $20.3M | $18.2M | ||
| Q3 24 | $6.1M | $18.0M | ||
| Q2 24 | $5.3M | $13.5M | ||
| Q1 24 | $8.0M | — |
| Q4 25 | $-232.5M | $-5.5M | ||
| Q3 25 | $-25.8M | $2.4M | ||
| Q2 25 | $-1.2M | $164.0K | ||
| Q1 25 | $-2.5M | $-3.6M | ||
| Q4 24 | $-2.5M | $6.5M | ||
| Q3 24 | $-3.2M | $3.2M | ||
| Q2 24 | $4.4M | $-2.2M | ||
| Q1 24 | $1.9M | — |
| Q4 25 | -13.0% | 49.4% | ||
| Q3 25 | -3.7% | 53.4% | ||
| Q2 25 | 16.4% | 62.5% | ||
| Q1 25 | 8.2% | 19.1% | ||
| Q4 24 | 8.2% | 78.7% | ||
| Q3 24 | 26.5% | 53.4% | ||
| Q2 24 | 25.1% | 29.8% | ||
| Q1 24 | 17.5% | — |
| Q4 25 | -475.0% | -51.1% | ||
| Q3 25 | -116.9% | 11.9% | ||
| Q2 25 | -15.9% | 7.5% | ||
| Q1 25 | -14.3% | -41.0% | ||
| Q4 24 | -11.9% | 39.6% | ||
| Q3 24 | -29.1% | 22.2% | ||
| Q2 24 | -16.4% | -18.0% | ||
| Q1 24 | -39.6% | — |
| Q4 25 | -2281.6% | -60.3% | ||
| Q3 25 | -487.6% | 13.2% | ||
| Q2 25 | -15.4% | 1.0% | ||
| Q1 25 | -25.7% | -35.8% | ||
| Q4 24 | -12.3% | 35.6% | ||
| Q3 24 | -52.5% | 18.0% | ||
| Q2 24 | 84.2% | -16.4% | ||
| Q1 24 | 24.4% | — |
| Q4 25 | $-2.34 | $-0.06 | ||
| Q3 25 | $-0.58 | $0.03 | ||
| Q2 25 | $-0.38 | $0.00 | ||
| Q1 25 | $-0.84 | $-0.05 | ||
| Q4 24 | $-1.44 | $0.10 | ||
| Q3 24 | $-1.77 | $0.03 | ||
| Q2 24 | $2.15 | $-0.03 | ||
| Q1 24 | $1.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.5M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $232.6M | $48.2M |
| Total Assets | $250.2M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.5M | $14.7M | ||
| Q3 25 | $23.7M | $13.6M | ||
| Q2 25 | $696.3K | $17.9M | ||
| Q1 25 | $434.4K | $19.5M | ||
| Q4 24 | $239.2K | $19.8M | ||
| Q3 24 | $2.4M | $27.4M | ||
| Q2 24 | $363.1K | $23.4M | ||
| Q1 24 | $808.8K | — |
| Q4 25 | $232.6M | $48.2M | ||
| Q3 25 | $339.2M | $52.9M | ||
| Q2 25 | $8.9M | $49.9M | ||
| Q1 25 | $9.7M | $45.2M | ||
| Q4 24 | $11.9M | $43.2M | ||
| Q3 24 | $13.0M | $32.4M | ||
| Q2 24 | $13.8M | $28.6M | ||
| Q1 24 | $3.9M | — |
| Q4 25 | $250.2M | $82.3M | ||
| Q3 25 | $355.5M | $82.3M | ||
| Q2 25 | $48.7M | $78.5M | ||
| Q1 25 | $47.6M | $73.9M | ||
| Q4 24 | $50.8M | $73.4M | ||
| Q3 24 | $49.2M | $61.6M | ||
| Q2 24 | $48.4M | $91.5M | ||
| Q1 24 | $50.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.0M | $2.0M |
| Free Cash FlowOCF − Capex | $-11.0M | $1.6M |
| FCF MarginFCF / Revenue | -107.7% | 17.8% |
| Capex IntensityCapex / Revenue | 0.0% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.0M | $2.0M | ||
| Q3 25 | $-1.6M | $-3.7M | ||
| Q2 25 | $-659.2K | $-5.2M | ||
| Q1 25 | $999.8K | $-5.1M | ||
| Q4 24 | $-6.6M | $4.0M | ||
| Q3 24 | $77.7K | $4.1M | ||
| Q2 24 | $-440.3K | $-3.6M | ||
| Q1 24 | $-723.3K | — |
| Q4 25 | $-11.0M | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-661.3K | $-5.7M | ||
| Q1 25 | $999.7K | $-5.4M | ||
| Q4 24 | $-6.6M | $3.6M | ||
| Q3 24 | $73.0K | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | -107.7% | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | -8.7% | -36.2% | ||
| Q1 25 | 10.1% | -53.0% | ||
| Q4 24 | -32.7% | 19.6% | ||
| Q3 24 | 1.2% | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | -0.10× | — | ||
| Q1 24 | -0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ORBS
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
